Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

Key Inclusion Criteria: * Subject or legally authorized representative must be able to understand and sign an approved Informed Consent Form. * Subject must have had bilateral implantation of Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOLs between 3-6 months prior to enrollment. * Subject must have a documented medical history and required pre-operative baseline information available for retrospective data collection. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Subject is currently participating in another investigational drug or device study. * Subject has had corneal refractive surgery after Clareon Vivity, Clareon Vivity Toric, Clareon PanOptix, or Clareon PanOptix Toric IOL implantation. * Subject is pregnant at the time of enrollment. * Other protocol-defined exclusion criteria may apply.